Efficacy and Tolerability of Fesoterodine in Men With Overactive Bladder: A Pooled Analysis of 2 Phase III Studies

Urology

Volumn 75, Issue 5, 2010, Pages 1149-1155

  Herschorn, Sender ^a   Jones, J Stephen ^b   Oelke, Matthias ^c   MacDiarmid, Scott ^d   Wang, Joseph T ^e   Guan, Zhonghong ^e  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b LERNER RESEARCH INSTITUTE   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Alliance Urology Specialists   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FESOTERODINE; PLACEBO; TOLTERODINE;

ARTICLE; BLADDER CATHETERIZATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY THROAT; DYSPEPSIA; DYSURIA; ENURESIS; HEADACHE; HEMATURIA; HUMAN; HYPERTENSION; NOCTURIA; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; URINE RETENTION; URINE VOLUME; XEROSTOMIA;

BENZHYDRYL COMPOUNDS; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; URINARY BLADDER, OVERACTIVE;

EID: 77951665928     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.09.007     Document Type: Article

References (30)

1. Abrams P., Artibani W., Cardozo L., et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 25 (2006) 293
2. Chapple C.R., and Roehrborn C.G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 49 (2006) 651-659
3. Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 20 (2003) 327-336
4. Irwin D.E., Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 50 (2006) 1306-1315
5. Oelke M., Baard J., Wijkstra H., et al. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol. 54 (2008) 419-426
6. Hyman M.J., Groutz A., and Blaivas J.G. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 166 (2001) 550-552
7. Lee J.Y., Kim H.W., Lee S.J., et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 94 (2004) 817-820
8. Machino R., Kakizaki H., Ameda K., et al. Detrusor instability with equivocal obstruction: a predictor of unfavorable symptomatic outcomes after transurethral prostatectomy. Neurourol Urodyn. 21 (2002) 444-449
9. Kaplan S.A., Roehrborn C.G., Dmochowski R., et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 68 (2006) 328-332
10. Roehrborn C.G., Abrams P., Rovner E.S., et al. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int. 97 (2006) 1003-1006
11. Dmochowski R., Abrams P., Marschall-Kehrel D., et al. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol. 51 (2007) 1054-1064
12. Kaplan S.A., Roehrborn C.G., Rovner E.S., et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. J Am Med Assoc. 296 (2006) 2319-2328
13. Kaplan S.A., Roehrborn C.G., Chancellor M., et al. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int. 102 (2008) 1133-1139
14. Rovner E.S., Kreder K., Sussman D.O., et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol. 180 (2008) 1034-1041
15. Athanasopoulos A., Gyftopoulos K., Giannitsas K., et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 169 (2003) 2253-2256
16. Yang Y., Zhao X.F., Li H.Z., et al. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J [Engl] 120 (2007) 370-374
17. Chapple C., Herschorn S., Abrams P., et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 56 (2009) 534-543
18. Kaplan S.A., Walmsley K., and Te A.E. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 174 (2005) 2273-2276
19. MacDiarmid S.A., Peters K.M., Chen A., et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 83 (2008) 1002-1010
20. Abrams P., Kaplan S.A., De Koning Gans H.J., et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 175 (2006) 999-1004
21. Michel M.C. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 9 (2008) 1787-1796
22. Chapple C., van Kerrebroeck P., Tubaro A., et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 52 (2007) 1204-1212
23. Nitti V., Dmochowski R., Sand P., et al. Efficacy, safety, and tolerability of fesoterodine in subjects with overactive bladder. J Urol. 178 (2007) 2488-2494
24. Kelleher C.J., Tubaro A., Wang J.T., et al. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int. 102 (2008) 56-61
25. Khullar V., Rovner E.S., Dmochowski R., et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 71 (2008) 839-843
26. Colman S., Chapple C., Nitti V., et al. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. Urology 72 (2008) 803-807
27. Kelly C.E. Evaluation of voiding dysfunction and measurement of bladder volume. Rev Urol. 6 Suppl 1 (2004) S32-S37
28. Gomez A., Martos F., Bellido I., et al. Muscarinic receptor subtypes in human and rat colon smooth muscle. Biochem Pharmacol. 43 (1992) 2413-2419
29. Peters T.J., Donovan J.L., Kay H.E., et al. The International Continence Society "Benign Prostatic Hyperplasia" Study: the bothersomeness of urinary symptoms. J Urol. 157 (1997) 885-889
30. Martín-Merino E., García-Rodríguez L.A.L.M.-G.E., et al. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention?. J Urol. 182 (2009) 1442-1448